2005
DOI: 10.1107/s0108767305084977
|View full text |Cite
|
Sign up to set email alerts
|

Crystal engineering of arylammonium perhalometallates

Abstract: Pharmaceutical co-crystallisation is emerging as a possible alternative to polymorphs, salts and solvates in the modification of an active pharmaceutical ingredient (API) during dosage form. It may alter the physico-chemical properties of the API (e.g. melting point and solubility), and also have intellectual property implications.Traditionally, co-crystallisation research has involved robust synthons with strong interactions and rarely involved pharmaceutically acceptable co-crystallising agents and condition… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...

Citation Types

0
0
0

Year Published

2010
2010
2010
2010

Publication Types

Select...
1

Relationship

0
1

Authors

Journals

citations
Cited by 1 publication
references
References 0 publications
0
0
0
Order By: Relevance